Filing Flows › Aytu Biopharma (AYTU) › Guidance & outlook
Aytu Biopharma (AYTU) guidance and outlook
Aytu Biopharma (AYTU) gave its guidance on Sep 22, 2026: EBITDA $500K for Q4 FY2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| EBITDA | Q4 FY2026 | $500K | new |
| Revenue | FY2026 | $6.6M | new |
| Revenue | Q4 FY2026 | $3.9M | new |
From the earnings release filed Sep 22, 2026 (8-K on EDGAR).
Aytu Biopharma's latest quarter
Aytu Biopharma, Q4 FY26: revenue $16.1M (+6% year over year), operating margin -4.8%, net loss $15K, operating cash flow $4.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Aytu Biopharma raise or lower its guidance?
Aytu Biopharma (AYTU) gave its guidance on Sep 22, 2026: EBITDA $500K for Q4 FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.